Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.


Updates from The Motley Fool

Latest updates on Myriad Genetics from Fool.com.  The Fool has written over 100 articles on Myriad Genetics.
The Nasdaq's 3 Most Hated Stocks

The Nasdaq Composite may be up 20% over the trailing 12-month period, but skeptics are piling int...

The Nasdaq's 3 Most Hated Stocks

The Nasdaq Composite has more than tripled since the recession, but pessimists have swarmed these...



Stock Performance

View Interactive MYGN Charts
Sponsored by

Key Data Points

Primary metrics and data points about Myriad Genetics.
Current Price: $17.94
Prev Close: $17.61
Open: $17.77
Bid: $17.93
Ask: $17.94
Day's Range: $17.75 - $18.04
52wk Range: $15.15 - $37.99
Volume: 248,213
Avg Vol 1,054,136
Market Cap: $1B
P/E (ttm): 20.48
EPS (ttm): $0.86
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Myriad Genetics.
CAPS Rating 4 out of 5
 
527 Outperform
87 Underperform
CAPS All Stars
 
110 Outperform
14 Underperform

How do you think Myriad Genetics will perform against the market?



You pick for Myriad Genetics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Mark C. Capone, CEO

69% Approve

Based on 39 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Myriad Genetics.

Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.

  • Exchange: NASDAQ
  • Sector: Services
  • Industry: Diversified Services